Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
- Caesarean section rates continue to rise, amid growing inequalities in access.(Available at:)https://www.who.int/news/item/16-06-2021-caesarean-section-rates-continue-to-rise-amid-growing-inequalities-in-access-whoDate accessed: September 8, 2021
- Long-term risks and benefits associated with cesarean delivery for mother, baby, and subsequent pregnancies: systematic review and meta-analysis.PLoS Med. 2018; 15e1002494
- Safe prevention of the primary cesarean delivery.(Available at:)https://www.acog.org/en/clinical/clinical-guidance/obstetric-care-consensus/articles/2014/03/safe-prevention-of-the-primary-cesarean-deliveryDate: 2014Date accessed: September 8, 2021
- Correlates of trial of labor and vaginal birth after cesarean in the United States.J Womens Health (Larchmt). 2019; 28: 1302-1312
- Induction of labor at 39 weeks of gestation versus expectant management for low-risk nulliparous women: a cost-effectiveness analysis.Am J Obstet Gynecol. 2019; 220: 590.e1-590.e10
- Benefits and risks of induction of labor at 39 or more weeks in uncomplicated nulliparous women: a retrospective, observational study.Obstet Gynecol Sci. 2019; 62: 19-26
- Elective induction of labor at 39 weeks among nulliparous women: the impact on maternal and neonatal risk.PLoS One. 2018; 13e0193169
- Timing of delivery and pregnancy outcomes among laboring nulliparous women.Am J Obstet Gynecol. 2012; 206: 239.e1-239.e8
- The risk of stillbirth and infant death by each additional week of expectant management stratified by maternal age.Am J Obstet Gynecol. 2013; 209: 375.e1-375.e7
- Labor induction versus expectant management in low-risk nulliparous women.N Engl J Med. 2018; 379: 513-523
- Elective induction of labor at 39 weeks compared with expectant management: a meta-analysis of cohort studies.Am J Obstet Gynecol. 2019; 221: 304-310
- ACOG response to ARRIVE trial.(Available at:)https://www.acog.org/news/news-releases/2018/02/acog-response-to-arrive-trialDate: 2020Date accessed: January 28, 2022
- The ARRIVE trial will not “arrive” to Europe.J Matern Fetal Neonatal Med. 2020; ([Epub ahead of print])
- The ARRIVE Trial: towards a universal recommendation of induction of labour at 39 weeks?.Eur J Obstet Gynecol Reprod Biol. 2020; 244: 192-195
- Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group.BMJ. 1998; 317: 465-468
- Stats of the states—cesarean delivery rates.(Available at:)https://www.cdc.gov/nchs/pressroom/sosmap/cesarean_births/cesareans.htmDate: 2021Date accessed: August 26, 2021
- Maternal and neonatal morbidity among nulliparous women undergoing elective induction of labor.J Reprod Med. 2011; 56: 25-30
- Outcomes of elective labour induction and elective caesarean section in low-risk pregnancies between 37 and 41 weeks’ gestation.J Obstet Gynaecol Can. 2009; 31: 1124-1130
- ACOG Practice Bulletin No. 107: induction of labor.Obstet Gynecol. 2009; 114: 386-397
- Elective induction compared with expectant management in nulliparous women with an unfavorable cervix.Obstet Gynecol. 2011; 117: 583-587
- Outcomes of elective induction of labour compared with expectant management: population based study.BMJ. 2012; 344: e2838
- Cigarette smoking among adults and trends in smoking cessation - United States, 2008.Morb Mortal Wkly Rep. 2009; 58: 1227-1232
- Trends in hospital-based childbirth care: the role of health insurance.Am J Manag Care. 2013; 19: e125-e132
The authors report no conflict of interest.
Cite this article as: Gilroy LC, Al-Kouatly HB, Minkoff HL, et al. Changes in obstetrical practices and pregnancy outcomes following the ARRIVE trial. Am J Obstet Gynecol 2022;226:716.e1-12.